Breakthrough Inhalable Nanoparticle Treatment Could Simplify Tuberculosis Care

Researchers at the University at Buffalo’s Jacobs School of Medicine have achieved a significant milestone in tuberculosis (TB) research, developing an inhalable nanoparticle treatment that could transform patient care. By utilizing a beta-glucan and chitosan-PLGA carrier, scientists successfully delivered rifampin directly to the lungs in mouse models. The findings, published in 'Antimicrobial Agents and Chemotherapy,' demonstrate that once-weekly doses of this inhaled therapy are as effective as the current standard of daily oral medication. This breakthrough addresses one of the primary obstacles in TB eradication: patient adherence. The demanding nature of daily, long-term oral therapy often leads to incomplete treatment and the subsequent development of drug-resistant strains. By shifting to a weekly, site-specific inhalable format, this technology promises to reduce side effects, improve patient compliance, and potentially revolutionize the global management of TB. While the transition from animal studies to human clinical trials remains the next critical step, this innovation marks a major advancement in targeted drug delivery and infectious disease management.